The new definition and classification of seizures and epilepsy
Jessica J Falco-Walter, Ingrid E Scheffer, Robert S Fisher
Epilepsy Research | ELSEVIER SCIENCE BV | Published : 2018
Jessica Falco-Walter has no financial interest or conflict of interest to declare. Ingrid Scheffer and Robert Fisher have no conflicts relevant to definition or classification of epilepsy. Robert Fisher has stock options in Avails Medical (testing of substance levels), Zeto (dry EEG), Cerebral Therapeutics (infusion of drugs into CSF), Smart Monitor (shake/seizure detector) and he consults for Engage Therapeutics. Ingrid Scheffer has served on scientific advisory boards for UCB, Eisai, GlaxoSmithKline and Nutricia; editorial boards of the Annals of Neurology, Neurology and Epileptic Disorders; may accrue future revenue on pending patent WO61/010176 (filed: 2008): Therapeutic Compound; has received speaker honoraria from GlaxoSmithKline, Athena Diagnostics, UCB, Eisai and Transgenomics; has received funding for travel from Athena Diagnostics, UCB, Biocodex, GlaxoSmithKline, and Eisai; and receives/has received research support from the National Health and Medical Research Council of Australia, National Institutes of Health, Australian Research Council, Health Research Council of New Zealand, CURE, American Epilepsy Society, US Department of Defense Autism Spectrum Disorder Research Program, March of Dimes, and Perpetual Charitable Trustees.